Although surgery is still the most effective treatment for diffuse glioma, patients with unresectable primary, recurrent, or multicentric illness have few options. In some cases, genotyping predictions may be useful for targeted therapy. We performed pretreatment MRI scans and genetic sequencing of tumor tissue, as well as correlation analysis, to see if essential molecular genetic events linked with diffuse glioma may be predicted in advance and noninvasively. The findings revealed that the MAP-MRI model can reliably predict tumor genotyping with high robustness and diagnostic validity, implying that it could be useful in the development of more standardized treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords